AD01 is a proprietary combination of topiramate and ondansetron, and shows a benefit for 1 out of 2 patients treated vs. currently marketed drugs that only benefit (approximately) 1 out of 10.

AD01 Status

Phase		Status	Timing
Pre-clinical*	First trials undertaken to determine drugs effects conducted in a laboratory or through controlled animal studies.	completed
Phase 0*	First-in-human trials undertaken to provide an early indication of new drugs effects in humans.	completed
Phase I*	Limited number human trials aimed at evaluating the safety, tolerability and effects of a new drug.	completed
Phase II*	Limited number of human trials undertaken to evaluate the effect of the combination drug vs either drug alone and vs placebo.	underway	Target completion date for this 320 patient study is the 3rd Quarter 2012.